Evidence map›Paper›PMID 18780892›Full record

ArticleScience signaling2008

Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development.

Elisa Ciraolo, Manuela Iezzi, Romina Marone, Stefano Marengo, Claudia Curcio, Carlotta Costa, Ornella Azzolino, Cristiano Gonella, Cristina Rubinetto, Haiyan Wu and 13 more

Open access · greenAbstract read
In one paragraph

Article in Science signaling, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 1 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 1 synthesis or guideline pooled it, 263 citations in OpenAlex.

  1. Pooled it
  2. A renaissance in targeting the PI3K/AKT/mTOR pathway.Nature reviews. Drug discovery · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. PI3K inhibitors in thrombosis and cardiovascular disease.Clinical and translational medicine · 2020
    Review

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 3 countries.

Elisa CiraoloDepartment of Genetics, Biology and Biochemistry, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126 Torino, Italy.
Manuela Iezzi
Romina Marone
Stefano Marengo
Claudia Curcio
Carlotta Costa
Ornella Azzolino
Cristiano Gonella
Cristina Rubinetto
Haiyan Wu
Walter Dastrù
Erica L Martin
Lorenzo Silengo
Fiorella Altruda
Emilia Turco
Letizia Lanzetti
Piero Musiani
Thomas Rückle
Christian Rommel
Jonathan M Backer
Guido Forni
Matthias P Wymann
Emilio Hirsch
Albert Einstein College of Medicine · USUniversity of Basel · CHUniversity of Chieti-Pescara · IT

Funding

P85/P110 PI 3 KINASE--STRUCTURE/FUNCTION AND PHYSIOLOGYR01GM055692 · NIGMS · YESHIVA UNIVERSITY · PI BACKER, JONATHAN M. · 1997 to 2013
$4.4M
NIGMS NIH HHS R01 GM055692Telethon GGP05113
6 · The paper itself

Abstract

The phosphoinositide 3-kinase (PI3K) pathway crucially controls metabolism and cell growth. Although different PI3K catalytic subunits are known to play distinct roles, the specific in vivo function of p110beta (the product of the PIK3CB gene) is not clear. Here, we show that mouse mutants expressing a catalytically inactive PIK3CB(K805R) mutant survived to adulthood but showed growth retardation and developed mild insulin resistance with age. Pharmacological and genetic analyses of p110beta function revealed that p110beta catalytic activity is required for PI3K signaling downstream of heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors as well as to sustain long-term insulin signaling. In addition, PIK3CB(K805R) mice were protected in a model of ERBB2-driven tumor development. These findings indicate an unexpected role for p110beta catalytic activity in diabetes and cancer, opening potential avenues for therapeutic intervention.

Indexed as

AgingAnimalsCells, CulturedCell Transformation, NeoplasticClass I Phosphatidylinositol 3-KinasesDiabetes Mellitus, ExperimentalEndocytosisErb-b2 Receptor Tyrosine KinasesInsulin ResistanceMammary Neoplasms, ExperimentalMiceMice, Mutant StrainsPhosphatidylinositol 3-KinasesSignal Transduction1-phosphatidylinositol 3-kinase p110 subunit, mouseClass I Phosphatidylinositol 3-KinasesErbb2 protein, mouseErb-b2 Receptor Tyrosine KinasesPhosphatidylinositol 3-Kinases

Identifiers

PMID18780892
PMCPMC2694958
OpenAlexW1991761103

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.